RAPID DIAGNOSTICS MARKET ANALYSIS

Market News

Global Rapid Diagnostics Market: Key Developments

In March 2022, Brain Chemistry Labs and Arlington Scientific teamed up to develop an easy-to-use rapid test kit. This kit will detect the presence of β-methylamino-L-Alanine (BMAA), a toxin present in cyanobacterial blooms, which may cause a fatal paralytic disease, called Amyotrophic Lateral Sclerosis (ALS).

In March 2022, GenBody America, LLC announced the opening and ramping up the production of anterior nasal swabs, which will be visually readable at its Jurupa Valley, California Factory. This facility will be capable of manufacturing 7.5 million such nasal swab kits per week.

In July 2021, IIT Hyderabad, India, developed an AI-powered rapid test kit for COVID-19 named COVIHOME. This test kit can detect symptomatic and asymptomatic patients in less than 30 minutes and can be performed without medical expert supervision.

In May 2021, Aster DM Healthcare and Roche Diagnostics signed Memorandum of Understanding (MoU). Through the partnership, Aster DM Healthcare’s hospitals, clinics, and laboratories across the region can now access advanced diagnostic technology offering efficient systems to support doctors in providing treatment solutions to their patients.

In May 2020, Quidel Corporation received Emergency Use Authorization (EUA) from the Food and drug administration for its Sofia 2 SARS Antigen FIA for rapid diagnosis of COVID-19.